Taysha Gene Therapies Inc. (TSHA) NASDAQ

$2.68 0.06 (2.29%)

Market Cap: $108.66M

As of 05/27/22 04:00 PM EDT. Market closed.

(TSHA)

Taysha Gene Therapies Inc. (TSHA) NASDAQ

$2.68 0.06 (2.29%)

Market Cap: $108.66M

As of 05/27/22 04:00 PM EDT. Market closed.

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an ... read more

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Full Time Employees
38
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$2.76
Previous Close
$2.62
Days Range
$2.55 - $2.71
52 week range
$2.33 - $26.99
Volume
266,902
Avg. Volume (30 days)
272,527
Market Cap
$108.66M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
40,546,392
Open
$2.76
Previous Close
$2.62
Days Range
$2.55 - $2.71
52 week range
$2.33 - $26.99
Volume
266,902
Avg. Volume (30 days)
272,527
Market Cap
$108.66M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
40,546,392

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR TAYSHA GENE THERAPIES INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Manning Paul B Director Feb 03, 2022 Buy $7.84 26,602 208,560 2,091,704 Feb 04, 2022, 08:28 AM
Manning Paul B Director Feb 03, 2022 Buy $7.84 50,000 392,000 142,202 Feb 04, 2022, 08:28 AM
Manning Paul B Director Feb 02, 2022 Buy $7.77 67,000 520,590 2,065,102 Feb 04, 2022, 08:28 AM
Manning Paul B Director Feb 02, 2022 Buy $7.77 58,000 450,660 92,202 Feb 04, 2022, 08:28 AM
Nagendran Sukumar Director Feb 02, 2022 Buy $8.01 10,000 80,100 29,226 Feb 03, 2022, 09:21 AM
Donenberg Phillip B. Director Feb 02, 2022 Buy $7.78 3,000 23,340 3,000 Feb 03, 2022, 07:04 AM
Session R.A. II President and CEO Nov 23, 2021 Buy $12.44 42,518 529,102 9,190,920 Dec 08, 2021, 04:05 PM
Manning Paul B Director Nov 24, 2021 Buy $13.19 2,202 29,044 34,202 Nov 29, 2021, 05:01 PM
Manning Paul B Director Nov 23, 2021 Buy $12.54 20,000 250,800 32,000 Nov 24, 2021, 07:58 AM
Alam Kamran Chief Financial Officer Aug 19, 2021 Sale $16.47 9,967 164,175 310,574 Aug 20, 2021, 05:52 PM
Alam Kamran Chief Financial Officer Aug 18, 2021 Sale $17.35 11,193 194,199 319,928 Aug 20, 2021, 05:52 PM
Alam Kamran Chief Financial Officer Aug 20, 2021 Sale $16.78 11,840 198,649 300,215 Aug 20, 2021, 05:52 PM
PRASAD SUYASH CMO and Head of R&D Jul 01, 2021 Sale $21.12 19,706 416,191 593,589 Jul 01, 2021, 06:32 PM
PRASAD SUYASH CMO and Head of R&D Jun 30, 2021 Sale $21.79 20,076 437,494 619,997 Jul 01, 2021, 06:32 PM
PRASAD SUYASH CMO and Head of R&D Jun 29, 2021 Sale $23.82 39,218 934,251 637,533 Jul 01, 2021, 06:32 PM
Manning Paul B Director May 14, 2021 Buy $20.98 12,000 251,760 12,000 May 17, 2021, 07:48 AM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Manning Paul B Director 02/03/2022 208,560
Manning Paul B Director 02/03/2022 392,000
Manning Paul B Director 02/02/2022 520,590
Manning Paul B Director 02/02/2022 450,660
Nagendran Sukumar Director 02/02/2022 80,100
Donenberg Phillip B. Director 02/02/2022 23,340
Session R.A. II President and CEO 11/23/2021 529,102
Manning Paul B Director 11/24/2021 29,044
Manning Paul B Director 11/23/2021 250,800
Alam Kamran Chief Financial Officer 08/19/2021 164,175
Alam Kamran Chief Financial Officer 08/18/2021 194,199
Alam Kamran Chief Financial Officer 08/20/2021 198,649
PRASAD SUYASH CMO and Head of R&D 07/01/2021 416,191
PRASAD SUYASH CMO and Head of R&D 06/30/2021 437,494
PRASAD SUYASH CMO and Head of R&D 06/29/2021 934,251
Manning Paul B Director 05/14/2021 251,760
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
06/30/2021
1.11%
2Q
12/31/2021
03/31/2021
1.78%
3Q

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2021
1.11%
2Q
03/31/2021
1.78%
3Q